
US FDA recalls tomatoes in 3 States due to deadly contamination: Know what the infection is and how to stay safe?
The US Food and Drug Administration (US FDA) has recalled tomatoes marketed by Williams Farms Repack LLC in Georgia, North Carolina & South Carolina. The tomatoes are not suitable for use due to possible Salmonella contamination.
Recently cucumbers grown by Bedner Growers, Inc., and distributed by Fresh Start Produce Sales, Inc., to retailers, distribution centers, wholesalers, and food service distributors were also recalled due to the same contamination.
What is
Salmonella infection
?
Salmonella is basically a bad bug (bacteria, to be exact) that sneaks into your system through contaminated food, mostly undercooked eggs, raw chicken, unwashed fruits, or even dirty hands.
Once it's in, it starts a party in your gut, and not the fun kind. You might end up stuck in the bathroom with cramps, diarrhea, fever, and feeling like you've been hit by a truck. It's super common and usually not serious for healthy people, but yeah, it's unpleasant.
Think of it as your body's way of saying, 'That chicken was shady.'
Is it deadly?
For most healthy people, Salmonella isn't deadly, it's just a miserable few days of stomach cramps, fever, and non-stop trips to the toilet.
But if you're super young, super old, or have a weak immune system, it can turn serious. In rare cases, it spreads beyond the gut to your bloodstream and organs. That's when it becomes dangerous and needs urgent medical attention. So while it's not usually life-threatening, it's definitely not something to ignore.
Best advice? Don't try to tough it out if things feel worse than just 'a bad stomach bug.'
How to stay safe?
Wash those hands like a surgeon, especially after touching raw meat, using the bathroom, or petting animals.
Cook your food properly (especially chicken and eggs), keep raw stuff away from ready-to-eat stuff, and don't eat cookie dough no matter how tempting it is. Rinse fruits and veggies, refrigerate leftovers fast, and avoid sketchy food joints. And if you're travelling, don't trust every street vendor with your digestive destiny.
Basically, treat your kitchen like a lab, and you'll be good. Prevention is boring, yes, but way better than spending 3 days hugging the toilet.
How to identify the symptoms?
If you suddenly get hit with a fever, stomach cramps, nausea, and diarrhea that just won't quit, Salmonella might be the villain. It usually shows up 6 to 72 hours after eating contaminated food and can stick around for 4 to 7 days. Some people also get chills, vomiting, and feel super tired. It's kinda like food poisoning on steroids. Most cases get better on their own with rest and fluids, but if you see blood in your stool or you can't keep anything down, it's time to see a doc.
Don't play doctor if it feels sketchy.
One step to a healthier you—join Times Health+ Yoga and feel the change

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
17 hours ago
- Time of India
Hyderabad cardiologist gets US patent for multi-functional cardiac occluder
File photo: Dr Nageswara Rao Koneti HYDERABAD: An innovative device that can fix various types of cardiac defects, designed by Hyderabad-based Dr Nageswara Rao Koneti, who heads the Cardiology Division at Rainbow Children's Heart Institute, has been granted a US patent. Called KONAR-MF Occluder, the multi-functional device can close septal defects in children and adults. It is a double umbrella disc device made of nitinol, a biocompatible nickel and titanium alloy, and is stretchable up to 15 mm. It can treat various conditions, including ventricular septal defects, coronary arteriovenous fistulas, and paravalvular leaks. The device has already been patented in India, Europe (European Commission), Euro-African countries, and South Korea. The multifunctional device not only fixes multiple types of cardiac lesions but also makes advanced cardiac care more affordable for patients in India, as it costs just Rs 50,000 in India compared to Rs 1.2 lakh in Pakistan and Rs 2.5–6 lakhs in other parts of Asia and Europe, said Dr Koneti. Terming this as a proud moment for Indian science, Dr Koneti said: "This US patent validates that innovations from India can meet global standards. It took us over six years to develop the device, and we applied for CE approval in 2018.' He said the US patent now paves the way for a US FDA (US Food and Drug Administration) approval for the device, which has already been implanted in about 10-15 patients in the US on compassionate grounds. "But we can also do clinical trials in the US if required," said Dr Koneti, who is a paediatric interventional cardiologist. He pointed out that the device has already demonstrated its safety and efficacy through over 20 peer-reviewed studies, and over 10,000 of these devices have already been implanted in patients in over 90 countries across Asia, Europe, Latin America, and Africa since the device got CE approval in 2018. The device is manufactured by LifeTech Scientific of China. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
&w=3840&q=100)

Business Standard
a day ago
- Business Standard
Gland Pharma share rises 2% in trade on Wednesday, June 4; here's why
Gland Pharma share price: Pharmaceutical company Gland Pharma shares increased as much as 1.58 per cent to hit an intraday high of 1,619 per share on Wednesday, June 4, 2025. At 11:10 AM, Gland Pharma shares continued to trade near day's high, up 1.33 per cent at 1615 per share. Why did Gland Pharma share price rise? Gland Pharma shares rose after it secured United States Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA) for Angiotensin II Acetate Injection 2.5 mg/mL. 'Gland Pharma Limited (Gland or Company), a generic injectable & ophthalmicfocused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Angiotensin II Acetate Injection 2.5 mg/mL,' Gland Pharma said, in a press release. Angiotensin II is a vasoconstrictor indicated for increasing blood pressure in adults with septic or other distributive shock. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Giapreza of La Jolla Pharma LLC, the company revealed. 'Gland Pharma is the exclusive First-to-File and is eligible for 180 days of generic drug exclusivity,' the company claimed. The product had US sales of approximately $58 million for the twelve months ending March 2025, according to IQVIA. Gland Pharma Q4 results Gland Pharma reported a 3 per cent year-on-year (YoY) decline in its consolidated net profit to ₹186.5 crore for the fourth quarter ended March 2025 (Q4FY25), compared to ₹192.4 crore in the same period last year. Revenue from operations fell 7 per cent YoY to ₹1,424.9 crore from ₹1,537.5 crore. The company's Ebitda stood at ₹347.5 crore, marginally down from ₹358.7 crore a year ago. However, the Ebitda margin improved to 24 per cent in Q4FY25, compared to 23 per cent in the corresponding quarter last year. Research and development (R&D) expenses during the quarter were ₹50.3 crore, accounting for 4.9 per cent of revenue. For the full financial year FY25, R&D expenses stood at ₹192.2 crore, or 4.7 per cent of annual revenue. Gland Pharma dividend About Gland Pharma Founded in 1978 in Hyderabad, Gland Pharma has evolved from a contract manufacturer of small-volume liquid parenterals to one of the largest injectable-focused pharmaceutical companies globally. Operating predominantly under a B2B model, it has a presence in over 60 countries, including the US, Europe, Canada, Australia, and India. The company's portfolio spans a wide range of sterile injectables such as vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, as well as oncology and ophthalmic products. Notably, it pioneered Heparin technology in India.


Business Standard
a day ago
- Business Standard
Gland Pharma gets US FDA approval for hypotension treatment drug Angiotensin II
Gland Pharma said that it has received approval from the United States Food and Drug Administration (US FDA) for its abbreviated new drug application (ANDA) for Angiotensin II Acetate Injection. The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD) GIAPREZA of La Jolla Pharma LLC. This product is indicated for increasing the blood pressure in adults with septic or other distributive shock. Gland Pharma is the exclusive first-to-file and is eligible for 180 days of generic drug exclusivity. According to IQVIA, the product had US sales of approximately $58 million for the twelve months ending March 2025. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered heparin technology in India. The company's consolidated net profit declined 3.06% to Rs 186.54 crore as net sales fell by 7.32% to Rs 1424.91 crore in Q4 FY25 as compared with Q4 FY24. The scrip rose 0.32% to currently trade at Rs 1598.95 on the BSE.